Brief: Kairos Pharma Adds Huntsman Cancer Institute For Phase 2 ENV105 Clinical Trial
11/02/2025 13:43
Feb 11 (Reuters) - Kairos Pharma Ltd KAPA.A :
* KAIROS PHARMA ADDS HUNTSMAN CANCER INSTITUTE FOR PHASE 2
ENV105
CLINICAL TRIAL
Source text: ID:nBwt5S08a
Further company coverage: KAPA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer